Bjerkli disputerer for ph.d.-graden i helsevitenskap og vil offentlig forsvare avhandlingen:
“Prognostic indicators of survival for patients with oral cavity squamous cell carcinoma in Norway. Outcomes in a retrospective, multicenter cohort, with special focus on oral tongue squamous cell carcinoma, 2005-2009”
Avhandlingen er tilgjengelig her / The doctoral thesis is available here
På grunn av koronautbruddet er auditoriet stengt for publikum. Disputasen vil i stedet bli strømmet. Opptak av disputasen vil være tilgjengelig i en måned.
The auditorium will be closed to the public because of the corona outbreak. The defense will be streamed. A recording of the disputation will be available for one month.
De som ønsker å opponere ex auditorio kan sende e-post til leder av disputasen (gunbjorg.svineng@uit.no). Opponents ex auditorio should sign up to leader of defense by e-mail (gunbjorg.svineng@uit.no).
Prøveforelesning over oppgitt emne starter kl. 10.15 / The trail lecture starts at 10.15
Tittel/Title: "Current palliative care and symptoms-relief for patients with oral cavity squamous cell carcinoma and future perspectives"
Prøveforelesningen strømmes her / The trail lecture will be streamed here
Disputasen starter kl. 12.15 / The defense starts at 12.15
Disputasen strømmes her / The defense will be streamed here
Populærvitenskapelig sammendrag av avhandlingen/ Summary of the thesis:
Cancer in the mouth is the most frequent of head and neck cancers, and very aggressive, with poor survival. The treatment is based on the presence of tumor (T), lymph node (N), and metastasis (M), although tumors with the same TNM classification may act differently in aggressiveness. Treatment is a combination of surgery, radiotherapy, and rarely chemotherapy.
Tumor growth patterns may predict the aggressiveness of the tumor, and if this is found, patients can recieve more personalized treatment, minimizing overtreatment or undertreatment. The Norwegian oral cancer (NOROC) study may be the largest study on mouth cancer in Norway. We present a retrospective cohort.
We found 535 patients with first-time cancer in the mouth. Median age at diagnosis was 67 years. Five-year disease-specific survival was 52%. Within the mouth, the mobile tongue is the most common site of cancer, and we re-evaluated 150 histopthological tumor samples.
High-risk Human Papilloma Virus was not found. We found histopathological growth patterns that can predict aggressiveness, and suggest that these patterns can be added to the TNM classification for personalized treatment planning.
Veiledere/ Supervisors:
Hovedveileder/Main supervisor:
Professor Sonja Eriksson Steigen, Institutt for medisinsk biologi, Det helsevitenskapelige fakultet, UiT Norges arktiske universitet
Biveiledere/supervisors:
Professor Lars Uhlin Hansen, Institutt for medisinsk biologi, Det helsevitenskapelige fakultet, UiT Norges arktiske universitetet
Professor Elin S. Hadler-Olsen, Institutt for medisinsk biologi, Det helsevitenskapelige fakultet, UiT Norges arktiske universitetet
Førsteamanuensis Oddveig G.Rikardsen, Institutt for klinisk medisin, Det helsevitenskapelige fakultet, UiT Norges arktiske universitetet
Bedømmelseskomité/Defensecomitee:
Senior Scientist/dosent Alhadi Almangush University of Helsinki, Finland – 1. opponent
Professor Hans Jørgen Aarstad, Universitetet i Bergen – 2.opponent
Førsteamanuensis Anne Dragøy Hafstad, Institutt for medisinsk biologi, Det helsevitenskapelige fakultet, UiT Norges arktiske universitet – leder av komité
Disputasleder/ Leader of defense:
Gunbjørg Svineng, Institutt for medisinsk biologi, Det helsevitenskapelige fakultet, UiT Norges arktiske universitet
Når: 08.10.20 kl 10.15–16.00
Hvor: Strømmes fra auditorium Cortex
Sted: Digitalt
Målgruppe: Ansatte, Studenter, Gjester / eksterne, Inviterte
Kontakt: Andrea Jennerwein
E-post: andrea.jennerwein@uit.no